According to the latest financial report of NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10, the latest earnings per share (TTM) for the company is 0.34. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10's free cash flow? The latest report shows it as 70.39M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10 shows that the company's current ratio is 1.11, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10, the quick ratio is 0.65, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10? The latest ROE figure is 4.98%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10, the total asset return on investment (ROA) is 2.49%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10's latest financial report to see how their gross margin is doing - currently at 53.99%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10, the net profit margin is 15.13%, which is a good sign for its profitability.